NovoCure (NVCR) Capital Expenditures Growth (3y) (2017 - 2026)
NovoCure (NVCR) Capital Expenditures Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.20 Bn | 175.91 Bn | 6.27 Bn | 1.64% |
| 2 | Stryker | 128.87 Bn | 125.99 Bn | 3.81 Bn | 8.49% |
| 3 | Medtronic | 108.88 Bn | 99.66 Bn | 6.41 Bn | 8.89% |
| 4 | Boston Scientific | 68.33 Bn | 66.87 Bn | 3.61 Bn | 16.83% |
| 5 | Edwards Lifesciences | 47.31 Bn | 43.64 Bn | 1.29 Bn | 1.81% |
| 6 | Dexcom | 28.65 Bn | 27.53 Bn | 750.30 Mn | 0.84% |
| 7 | GE HealthCare Technologies | 28.40 Bn | 26.11 Bn | 1.98 Bn | 7.57% |
| 8 | Smith & Nephew | 26.97 Bn | 26.40 Bn | - | - |
| 9 | Koninklijke Philips | 25.55 Bn | 22.42 Bn | 2.07 Bn | 2.15% |
| 10 | NovoCure | 2.01 Bn | 1.57 Bn | 142.48 Mn | -0.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.07% |
| Mar 31, 2026 | -5.41% |
| Dec 31, 2025 | -8.69% |
| Sep 30, 2025 | -0.28% |
| Jun 30, 2025 | 9.92% |
| Mar 31, 2025 | 27.72% |
| Dec 31, 2024 | -14.43% |
| Sep 30, 2024 | 47.98% |
| Jun 30, 2024 | 63.52% |
| Mar 31, 2024 | 43.58% |
| Dec 31, 2023 | 5.80% |
| Sep 30, 2023 | 11.92% |
| Jun 30, 2023 | 27.87% |
| Mar 31, 2023 | 25.07% |
| Dec 31, 2022 | 28.16% |
| Sep 30, 2022 | 28.18% |
| Jun 30, 2022 | 19.89% |
| Mar 31, 2022 | 29.87% |
| Dec 31, 2021 | 99.67% |
| Sep 30, 2021 | 34.57% |